In a study conducted by Martina and colleagues [161], it was suggested that glutathione administration in individuals with type II diabetes enhanced platelet constitutive NOS (cNOS) activity and concurrently decreased plasminogen activator inhibitor-1 (Pal-1). Here, NOS3 is linked to type 2 diabetes mellitus.